De
Dermira (Lilly)
Menlo Park CAFounded 2010200 employees
Private CapbiotechAcquiredDermatology
Platform: Lebrikizumab AD
Market Cap
N/A
All Drugs
4
Clinical Trials
7
Failed / Terminated
1
FDA Approved
1
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Gozemavacamten | DER-9261 | Approved | 3 | CD20 | Cervical CaAlzheimer's | ||
| DER-2537 | DER-2537 | Phase 2/3 | 1 | PSMA | IgAN | ||
| DER-1141 | DER-1141 | Preclinical | 2 | FcRn | MCL | ||
| DER-3666 | DER-3666 | Phase 2/3 | 1 | KRASG12C | SMA |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (7)